Legend Biotech awards director 20,986 share units

One-third of the RSUs will vest on December 20, 2027, with the remainder subject to 12 quarterly installments beginning March 20, 2028, contingent on continued service.

Rhea-AI Filing Summary

Legend Biotech Corp (LEGN) director Corazon (Corsee) D. Sanders received an award of 20,986 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share. One-third will vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to continued service on each vesting date. Reported direct holdings following the award were 80,101 shares.

Insider Trade Summary

Grant/Award: 20,986 shares

Grant/Award 1 txn

Insider Sanders Corazon (Corsee) D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1, F2	20,986	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 80,101 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Restricted share units awarded: 20,986 RSUs Direct holdings after transaction: 80,101 shares Initial vesting portion: 1/3 of the RSUs +1 more

4 metrics

Restricted share units awarded 20,986 RSUs Awarded September 24, 2026

Direct holdings after transaction 80,101 shares Reported following the September 24, 2026 award

Initial vesting portion 1/3 of the RSUs Will vest on December 20, 2027, subject to continued service

Subsequent vesting installments 12 equal quarterly installments Beginning March 20, 2028, subject to continued service

Key Terms

restricted share units, contingent right, American Depositary Shares

3 terms

restricted share units financial

"Represents restricted share units (the "RSUs")."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

contingent right financial

"Each RSU represents a contingent right to receive one ordinary share"

American Depositary Shares financial

"may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs did Legend Biotech (LEGN) director Corazon Sanders receive?

Corazon (Corsee) D. Sanders received an award of 20,986 restricted share units on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share.

When do Corazon Sanders’s Legend Biotech RSUs vest?

One-third of the RSUs will vest on December 20, 2027, and the remainder will vest in 12 equal quarterly installments beginning March 20, 2028. Vesting is subject to the reporting person’s continued service to Legend Biotech on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 04:10 PM Accepted by SEC EDGAR 09/28/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanders Corazon (Corsee) D.

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

77 CORPORATE DRIVE, 4TH FLOOR

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/24/2026		A		20,986(2)	A	$0	80,101	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Robert Staloff, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)